2026-04-14T06:21:59Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4689782026-03-28T08:47:39Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Álvarez Palomo, Belén author Veiga, Anna author Raya, Ángel author Codinach, Margarita author Torrents, Silvia author Ponce Verdugo, Laura author Rodriguez-Aierbe, Clara author Cuellar, Leopoldo author Alenda, Raquel author Arbona, Cristina author Hernández-Maraver, Dolores author Fusté, Cristina author Querol, Sergi author Universitat Autònoma de Barcelona author 2022 The increasing number of clinical trials for induced pluripotent stem cell (iPSC)-derived cell therapy products makes the production on clinical grade iPSC more and more relevant and necessary. Cord blood banks are an ideal source of young, HLA-typed and virus screened starting material to produce HLA-homozygous iPSC lines for wide immune-compatibility allogenic cell therapy approaches. The production of such clinical grade iPSC lines (haplolines) involves particular attention to all steps since donor informed consent, cell procurement and a GMP-compliant cell isolation process. Homozygous cord blood units were identified and quality verified before recontacting donors for informed consent. CD34+ cells were purified from the mononuclear fraction isolated in a cell processor, by magnetic microbeads labelling and separation columns. We obtained a median recovery of 20.0% of the collected pre-freezing CD34+, with a final product median viability of 99.1% and median purity of 83.5% of the post-thawed purified CD34+ population. Here we describe our own experience, from unit selection and donor reconsenting, in generating a CD34+ cell product as a starting material to produce HLA-homozygous iPSC following a cost-effective and clinical grade-compliant procedure. These CD34+ cells are the basis for the Spanish bank of haplolines envisioned to serve as a source of cell products for clinical research and therapy. The online version contains supplementary material available at 10.1186/s13287-022-02961-6. Hematopoietic progenitor cells Cord blood Cord blood banks Induced pluripotent stem cells HLA matching GMP manufacturing Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells